Heat Shock Protein 105 (HSP105) peptide-pulsed dendritic cell vaccination therapy for patients with advanced/ recurrent cancer.
Phase of Trial: Phase II
Latest Information Update: 13 May 2016
At a glance
- Drugs HSP105 peptide-loaded dendritic cell vaccine (Primary)
- Indications Cancer
- Focus Adverse reactions
- 25 Nov 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 27 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 16 Nov 2011 New trial record